Cargando…

Assessment of Antifungal Pharmacodynamics

Pharmacokinetic-pharmacodynamic (PK-PD) analysis is of central importance to the progress of an antifungal agent into clinical use. It is crucial to ensure that preclinical studies give the best possible prediction of the way drugs are likely to behave in a clinical setting. This review details the...

Descripción completa

Detalles Bibliográficos
Autores principales: Howard, Alex, Hope, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960731/
https://www.ncbi.nlm.nih.gov/pubmed/36836307
http://dx.doi.org/10.3390/jof9020192
_version_ 1784895580969893888
author Howard, Alex
Hope, William
author_facet Howard, Alex
Hope, William
author_sort Howard, Alex
collection PubMed
description Pharmacokinetic-pharmacodynamic (PK-PD) analysis is of central importance to the progress of an antifungal agent into clinical use. It is crucial to ensure that preclinical studies give the best possible prediction of the way drugs are likely to behave in a clinical setting. This review details the last 30 years of progress in terms of disease model design, efficacy outcome selection and translational modelling in antifungal PK-PD studies. The principles of how PK-PD parameters inform current clinical practice are also discussed, including a review of how these apply to existing and novel agents.
format Online
Article
Text
id pubmed-9960731
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99607312023-02-26 Assessment of Antifungal Pharmacodynamics Howard, Alex Hope, William J Fungi (Basel) Opinion Pharmacokinetic-pharmacodynamic (PK-PD) analysis is of central importance to the progress of an antifungal agent into clinical use. It is crucial to ensure that preclinical studies give the best possible prediction of the way drugs are likely to behave in a clinical setting. This review details the last 30 years of progress in terms of disease model design, efficacy outcome selection and translational modelling in antifungal PK-PD studies. The principles of how PK-PD parameters inform current clinical practice are also discussed, including a review of how these apply to existing and novel agents. MDPI 2023-02-01 /pmc/articles/PMC9960731/ /pubmed/36836307 http://dx.doi.org/10.3390/jof9020192 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Opinion
Howard, Alex
Hope, William
Assessment of Antifungal Pharmacodynamics
title Assessment of Antifungal Pharmacodynamics
title_full Assessment of Antifungal Pharmacodynamics
title_fullStr Assessment of Antifungal Pharmacodynamics
title_full_unstemmed Assessment of Antifungal Pharmacodynamics
title_short Assessment of Antifungal Pharmacodynamics
title_sort assessment of antifungal pharmacodynamics
topic Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960731/
https://www.ncbi.nlm.nih.gov/pubmed/36836307
http://dx.doi.org/10.3390/jof9020192
work_keys_str_mv AT howardalex assessmentofantifungalpharmacodynamics
AT hopewilliam assessmentofantifungalpharmacodynamics